HMGCR and diabetic kidney disease: The present study addressed the above mentioned issues by using two mechanistically distinct means to lower circulating cholesterol, i.e., HMG-CoA reductase inhibition and GI-cholesterol binding on severity of diabetic nephropathy in streptozotocin induced diabetic nephropathy.